Postmenopausal estrogen and progestin effects on the serum proteome
Authors:
- Sharon J PitteriSPSharon J Pitteri
- Samir M HanashSHSamir M Hanash
- Aaron AragakiAAAaron Aragaki
- Lynn M AmonLALynn M Amon
- Lin ChenLCLin Chen
- Tina Busald BusonTBTina Busald Buson
- Sophie PaczesnySPSophie Paczesny
- Hiroyuki KatayamaHKHiroyuki Katayama
- Hong WangHWHong Wang
- Melissa M JohnsonMJMelissa M Johnson
- Qing ZhangQZQing Zhang
- Martin McIntoshMMMartin McIntosh
Open Access
- 24 December 2009
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 1 (12) , 121
Abstract
Background: Women's Health Initiative randomized trials of postmenopausal hormone therapy reported intervention effects on several clinical outcomes, with some important differences between estrogen alone and estrogen plus progestin. The biologic mechanisms underlying these effects, and these differences, have yet to be fully elucidated. Methods: Baseline serum samples were compared with samples drawn 1 year later for 50 women assigned to active hormone therapy in both the estrogen-plus-progestin and estrogen-alone randomized trials, by applying an in-depth proteomic discovery platform to serum pools from 10 women per pool. Results: In total, 378 proteins were quantified in two or more of the 10 pooled serum comparisons, by using strict identification criteria. Of these, 169 (44.7%) showed evidence (nominal P < 0.05) of change in concentration between baseline and 1 year for one or both of estrogen-plus-progestin and estrogen-alone groups. Quantitative changes were highly correlated between the two hormone-therapy preparations. A total of 98 proteins had false discovery rates < 0.05 for change with estrogen plus progestin, compared with 94 for estrogen alone. Of these, 84 had false discovery rates <0.05 for both preparations. The observed changes included multiple proteins relevant to coagulation, inflammation, immune response, metabolism, cell adhesion, growth factors, and osteogenesis. Evidence of differential changes also was noted between the hormone preparations, with the strongest evidence in growth factor and inflammation pathways. Conclusions: Serum proteomic analyses yielded a large number of proteins similarly affected by estrogen plus progestin and by estrogen alone and identified some proteins and pathways that appear to be differentially affected between the two hormone preparations; this may explain their distinct clinical effects.Keywords
This publication has 43 references indexed in Scilit:
- Serum levels of IGF‐I, IGFBP‐3 and colorectal cancer risk: results from the EPIC cohort, plus a meta‐analysis of prospective studiesInternational Journal of Cancer, 2010
- Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.2008
- Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trialsClinical Trials, 2007
- Inflammation in AtherosclerosisCirculation, 2006
- Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With HysterectomyJAMA, 2006
- Analysis of Intimal Proteoglycans in Atherosclerosis-prone and Atherosclerosis-resistant Human Arteries by Mass SpectrometryMolecular & Cellular Proteomics, 2005
- The insulin-like growth factor system and colorectal cancer: clinical and experimental evidenceInternational Journal of Colorectal Disease, 2005
- Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral DensityThe Women's Health Initiative Randomized TrialJAMA, 2003
- Effect of Estrogen Plus Progestin on Stroke in Postmenopausal WomenJAMA, 2003
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002